Detalhe da pesquisa
1.
Enhancing global access to cancer medicines.
CA Cancer J Clin
; 70(2): 105-124, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068901
2.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38582092
3.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 387(3): 217-226, 2022 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35857659
4.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495879
5.
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat
; 2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456970
6.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587643
7.
Analysis of the Photogrammetric Use of 360-Degree Cameras in Complex Heritage-Related Scenes: Case of the Necropolis of Qubbet el-Hawa (Aswan Egypt).
Sensors (Basel)
; 24(7)2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38610481
8.
Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer.
Int J Mol Sci
; 25(7)2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38612751
9.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239405
10.
Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain.
Int J Mol Sci
; 24(15)2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37569408
11.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36300423
12.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019819
13.
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Br J Cancer
; 124(9): 1581-1591, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33723394
14.
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Breast Cancer Res Treat
; 187(2): 467-476, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33748921
15.
New approach to cancer therapy based on a molecularly defined cancer classification.
CA Cancer J Clin
; 64(1): 70-4, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24249308
16.
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 22(1): 9, 2020 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31969184
17.
Can we cure oligometastatic disease? A practical point of view.
Curr Opin Oncol
; 32(6): 568-574, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32925203
18.
Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.
Biochim Biophys Acta Rev Cancer
; 1868(2): 527-537, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29061314
19.
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Res
; 21(1): 133, 2019 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31796073
20.
Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
Oncologist
; 24(8): 1041-1047, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30578311